Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Myeloid leukemia after hematotoxins

R A Larson1, M M LeBeau, J W Vardiman

  • 1Department of Medicine, University of Chicago, Illinois 60637-1470, USA. ralarson@mcis.bsd.uchicago.edu

Environmental Health Perspectives
|December 1, 1996
PubMed
Summary

Cancer therapy can lead to secondary leukemia. Distinct subtypes exist, including classic myeloid leukemia and therapy-related leukemias with specific genetic rearrangements, influencing prognosis and treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Survival Experience of 195 Patients with Hairy Cell Leukemia Treated in a Multi-Institutional Study with Interferon-Alfa 2B.

Leukemia & lymphoma·2016
Same author

Familial Lymphoproliferative Disorders with Chromosomal Fragile Site Analysis.

Leukemia & lymphoma·2016
Same author

No chromosome arm unturned: in memory of Roland Berger 1934-2012.

Leukemia·2014
Same author

Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome.

Leukemia·2013
Same author

Broadband terahertz pulse emission from ZnGeP2.

Optics letters·2012
Same author

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.

Leukemia·2007

Area of Science:

  • Oncology
  • Hematology
  • Cancer Genetics

Background:

  • Cancer therapy, while life-saving, carries the risk of secondary malignancies, particularly leukemia.
  • Distinguishing between different types of therapy-related leukemia is crucial for understanding their distinct characteristics and outcomes.

Purpose of the Study:

  • To differentiate and characterize distinct subsets of therapy-related leukemia.
  • To elucidate the varying latency periods, clinical phenotypes, and genetic abnormalities associated with different therapy-induced leukemias.

Main Methods:

  • Review and synthesis of existing literature on therapy-related leukemias.
  • Analysis of clinical and genetic features of distinct leukemia subtypes.
  • Comparison of therapy-related leukemias with de novo leukemia counterparts.

Main Results:

  • Classic therapy-related myeloid leukemia (t-ML) presents with a longer latency (5-7 years), myelodysplastic phase, and chromosomal abnormalities (5q/7q).
  • Topoisomerase II inhibitor-related leukemias exhibit shorter latency, monoblastic/myelomonocytic phenotypes, and specific translocations (11q23, 21q22) involving MLL or AML1 genes.
  • Therapy-related acute lymphoblastic leukemia (t-ALL) also shows 11q23 rearrangements.
  • Leukemias with 11q23/21q22 rearrangements, inv(16), or t(15;17) demonstrate a more favorable prognosis.

Conclusions:

  • Therapy-related leukemias are heterogeneous, with distinct subtypes arising from different treatments and characterized by specific genetic alterations.
  • Understanding these subtypes is essential for predicting prognosis and guiding treatment decisions, including bone marrow transplantation for poor-prognosis cases.
  • Certain genetic rearrangements in therapy-related leukemias correlate with a better response to treatment, similar to de novo cases.

Related Experiment Videos